ZOM Quote, Financials, Valuation and Earnings

Ainos has a net margin of -95.71% compared to Zomedica's net margin of -15991.17%. Zomedica's return on equity of -27.17% beat Ainos's return on equity of -52.95%.

Zomedica has a consensus price target of --, signalling upside risk potential of 108.33%. On the other hand Ainos has an analysts' consensus of -- which suggests that it could fall by --. Given that Zomedica has higher upside potential than Ainos, analysts believe Zomedica is more attractive than Ainos.

Zomedica has a beta of 1.044, which suggesting that the stock is 4.385% more volatile than S&P 500. In comparison Ainos has a beta of 1.417, suggesting its more volatile than the S&P 500 by 41.704%.

Zomedica has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ainos offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zomedica pays -- of its earnings as a dividend. Ainos pays out -- of its earnings as a dividend.

Zomedica quarterly revenues are $7M, which are larger than Ainos quarterly revenues of $20.7K. Zomedica's net income of -$6.7M is lower than Ainos's net income of -$3.7M. Notably, Zomedica's price-to-earnings ratio is -- while Ainos's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zomedica is 4.40x versus 34.77x for Ainos. Usually stocks with elevated PS ratios are considered overvalued.

Intelligent Bio Solutions has a net margin of -95.71% compared to Zomedica's net margin of -307.88%. Zomedica's return on equity of -27.17% beat Intelligent Bio Solutions's return on equity of -176.44%.

Zomedica has a consensus price target of --, signalling upside risk potential of 108.33%. On the other hand Intelligent Bio Solutions has an analysts' consensus of -- which suggests that it could grow by 782.35%. Given that Intelligent Bio Solutions has higher upside potential than Zomedica, analysts believe Intelligent Bio Solutions is more attractive than Zomedica.

Zomedica has a beta of 1.044, which suggesting that the stock is 4.385% more volatile than S&P 500. In comparison Intelligent Bio Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Zomedica has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zomedica pays -- of its earnings as a dividend. Intelligent Bio Solutions pays out -- of its earnings as a dividend.

Zomedica quarterly revenues are $7M, which are larger than Intelligent Bio Solutions quarterly revenues of $872.3K. Zomedica's net income of -$6.7M is lower than Intelligent Bio Solutions's net income of -$2.7M. Notably, Zomedica's price-to-earnings ratio is -- while Intelligent Bio Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zomedica is 4.40x versus 0.63x for Intelligent Bio Solutions. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools has a net margin of -95.71% compared to Zomedica's net margin of -59.9%. Zomedica's return on equity of -27.17% beat Standard BioTools's return on equity of -48.03%.

Zomedica has a consensus price target of --, signalling upside risk potential of 108.33%. On the other hand Standard BioTools has an analysts' consensus of -- which suggests that it could grow by 68.49%. Given that Zomedica has higher upside potential than Standard BioTools, analysts believe Zomedica is more attractive than Standard BioTools.

Zomedica has a beta of 1.044, which suggesting that the stock is 4.385% more volatile than S&P 500. In comparison Standard BioTools has a beta of 1.606, suggesting its more volatile than the S&P 500 by 60.617%.

Zomedica has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zomedica pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.

Zomedica quarterly revenues are $7M, which are smaller than Standard BioTools quarterly revenues of $45M. Zomedica's net income of -$6.7M is higher than Standard BioTools's net income of -$26.9M. Notably, Zomedica's price-to-earnings ratio is -- while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zomedica is 4.40x versus 3.28x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR has a net margin of -95.71% compared to Zomedica's net margin of -11.09%. Zomedica's return on equity of -27.17% beat LENSAR's return on equity of -56.16%.

Zomedica has a consensus price target of --, signalling upside risk potential of 108.33%. On the other hand LENSAR has an analysts' consensus of -- which suggests that it could grow by 26.58%. Given that Zomedica has higher upside potential than LENSAR, analysts believe Zomedica is more attractive than LENSAR.

Zomedica has a beta of 1.044, which suggesting that the stock is 4.385% more volatile than S&P 500. In comparison LENSAR has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Zomedica has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zomedica pays -- of its earnings as a dividend. LENSAR pays out -- of its earnings as a dividend.

Zomedica quarterly revenues are $7M, which are smaller than LENSAR quarterly revenues of $13.5M. Zomedica's net income of -$6.7M is lower than LENSAR's net income of -$1.5M. Notably, Zomedica's price-to-earnings ratio is -- while LENSAR's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zomedica is 4.40x versus 2.03x for LENSAR. Usually stocks with elevated PS ratios are considered overvalued.